Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $275.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price raised by Barclays from $271.00 to $275.00 in a report published on Tuesday,Benzinga reports. Barclays currently has an overweight rating on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently weighed in on the company. TD Cowen boosted their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Wells Fargo & Company raised their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft raised their price target on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Finally, UBS Group boosted their price objective on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a research report on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $293.45.

Jazz Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ JAZZ opened at $227.32 on Tuesday. The business’s 50 day moving average is $229.71 and its two-hundred day moving average is $217.40. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.58. Jazz Pharmaceuticals has a 1-year low of $128.80 and a 1-year high of $266.38. The stock has a market capitalization of $14.59 billion, a P/E ratio of 20.80, a PEG ratio of 0.47 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business posted $8.13 earnings per share. As a group, research analysts expect that Jazz Pharmaceuticals will post 10.84 EPS for the current year.

Insider Activity

In other news, EVP Robert Iannone sold 76,921 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the transaction, the executive vice president owned 65,686 shares of the company’s stock, valued at approximately $16,401,794.20. This represents a 53.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $215.84, for a total value of $1,295,040.00. Following the completion of the sale, the director owned 339,875 shares in the company, valued at approximately $73,358,620. The trade was a 1.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 101,121 shares of company stock worth $24,858,332 in the last ninety days. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Maryland State Retirement & Pension System increased its stake in Jazz Pharmaceuticals by 19.0% in the third quarter. Maryland State Retirement & Pension System now owns 3,633 shares of the specialty pharmaceutical company’s stock worth $841,000 after purchasing an additional 580 shares during the period. Lido Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 5.2% during the third quarter. Lido Advisors LLC now owns 2,644 shares of the specialty pharmaceutical company’s stock valued at $612,000 after purchasing an additional 131 shares during the period. Keybank National Association OH boosted its stake in shares of Jazz Pharmaceuticals by 0.6% during the third quarter. Keybank National Association OH now owns 10,141 shares of the specialty pharmaceutical company’s stock valued at $2,348,000 after purchasing an additional 57 shares during the period. Csenge Advisory Group boosted its stake in shares of Jazz Pharmaceuticals by 4.1% during the third quarter. Csenge Advisory Group now owns 5,242 shares of the specialty pharmaceutical company’s stock valued at $1,214,000 after purchasing an additional 205 shares during the period. Finally, Penn Capital Management Company LLC bought a new position in shares of Jazz Pharmaceuticals in the third quarter worth about $1,009,000. Institutional investors own 89.14% of the company’s stock.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
• Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.